{"id":"28b98b0cf88f","type":"article","url":"https://hartvaat.nl/2018/01/23/empagliflozine-bij-diabetes-type-2-met-perifeer-vaatlijden-empa-reg-outcome/","title":"Empagliflozine bij diabetes type 2 met perifeer vaatlijden: EMPA-REG OUTCOME","title_en":"Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["diabetes-type-2","empagliflozine","soul-trial"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.117.032031","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.117.032031","authors":["Subodh Verma","C David Mazer","Mohammed Al-Omran","Silvio E Inzucchi","David Fitchett","Uwe Hehnke","Jyothis T George","Bernard Zinman"],"significance":7,"published":"2018-01-23","source_date":"2018-01-23","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This EMPA-REG OUTCOME subanalysis showed that empagliflozin's cardiovascular benefit is preserved in diabetic patients with peripheral arterial disease, a particularly high-risk population with elevated limb and cardiovascular event rates.","created":"2026-07-03T10:27:06Z","updated":"2026-07-03T13:26:22Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"EMPA-REG OUTCOME subanalyse bij diabetespatiënten met perifeer arterieel vaatlijden — een hoogrisicopopulatie. Cardiovasculaire veiligheid en potentieel voordeel bevestigd.","abstract_original":""}